
```
C:\STNEXP4\QUERIES\500849c.str
```

```
chain nodes :
   24
ring nodes :
   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
   22 23 26 27 28 29
                        30
chain bonds :
   19-24
ring bonds :
   1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 8-13 10-11
   10-14
         11-12 11-16 12-13 12-17
                                  13-19 14-15 15-16
                                                      17-18 17-20
   18-19
         18-23
                20-21 21-22 22-23
                                  26-27 26-31 27-28
                                                      28-29 29-30
   30-31
exact/norm bonds :
   5-7 6-9 8-9 10-14 11-16 12-17 13-19 14-15 15-16 17-18 17-20
   18-19 18-23 20-21 21-22 22-23 26-27 26-31 27-28 28-29 29-30
   30-31
exact bonds :
   19-24
normalized bonds :
   1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-10 8-13 10-11 11-12 12-13
isolated ring systems :
   containing 1 :
Match level :
   1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
   10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
   18:Atom
```

19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS



ENTER (DIS), GRA, NOD, BON OR ?:end L7 STRUCTURE CREATED

=> s 17

SAMPLE SEARCH INITIATED 08:45:23 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 164 TO ITERATE

100.0% PROCESSED 164 ITERATIONS

SEARCH TIME: 00.00.01

TIONS 0 ANSWERS

26 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

2512 TO 4048

PROJECTED ANSWERS:

0 TO 0

L8 0 SEA SSS SAM L7

=> s 17 ful

FULL SEARCH INITIATED 08:45:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3354 TO ITERATE

100.0% PROCESSED 3354 ITERATIONS

SEARCH TIME: 00.00.02

L9 26 SEA SSS FUL L7

```
L10
             10 L9
=> d bib abs 1-10
L10 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS
     2002:142907 CAPLUS
AN
DN
     136:194260
тT
     Methods for modulating multiple lineage kinase proteins and screening
     compounds which modulate multiple linease kinase proteins
ΙN
     Maroney, Anna; Walton, Kevin M.; Dionne, Craig A.; Neff, Nicola; Knight,
     Ernest, Jr.; Glicksman, Marcie A.
PA
     Cephalon, Inc., USA
     PCT Int. Appl., 114 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LΑ
     English
FAN.CNT 1
     PATENT NO.
                   KIND DATE
                                            APPLICATION NO. DATE
                       ----
                                             -----
     WO 2002014536 A2 20020221
                                        WO 2001-US24822 20010808
PT
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
              RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
         VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-637054
                        Α
                              20000811
OS
     MARPAT 136:194260
     Methods for identifying compds. which modulate activity of a multiple
AΒ
     linease kinase protein and promotes cell survival or cell death comprising
     the steps of contacting the cell contg. the multiple linease protein with
     the compd., detg. whether the compd. decreases activity of the multiple
     linease protein, and detg. whether the compd. promotes cell survival are
     provided. Methods for identifying compds. which may be useful in the
     treatment of neurodegenerative disorders and/or inflammation are also
     provided. Methods for modulating the activity of a multiple linage kinase
     protein comprising contacting the protein or a cell contg. the protein
     with an indeno- or indolo-compd. of the invention are also provided.
     Methods of treating neurodegenerative disorders and/or inflammation are
     also provided.
     ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS
L10
AN
     2000:573797 CAPLUS
DN
ΤI
     Preparation of cyclic substituted fused pyrrolocarbazoles and isoindolones
     with protein kinase inhibiting activity for pharmaceutical use
     Hudkins, Robert L.; Reddy, Dandu; Singh, Jasbir; Stripathy, Rabindranath;
IN
     Underiner, Theodore L.
PΑ
     Cephalon, Inc., USA
     PCT Int. Appl., 131 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                             APPLICATION NO. DATE
PΙ
     WO 2000047583
                      A1
                             20000817
                                             WO 2000-US3476
                                                               20000211
         W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
```

=> s 19

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1165562 EP 2000-911759 A1 20020102 20000211 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO BR 2000-8056 BR 2000008056 20020409 20000211 Α NO 2001003887 20011011 NO 2001-3887 20010809 Α PRAI US 1999-119834P Р 19990212 US 2000-500849 Α 20000210 WO 2000-US3476 W 20000211 MARPAT 133:177158 OS GI

AB Fused pyrrolocarbazoles and isoindolones, such as I [R1 = H, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; R3-6 = H, CN, CF3, OH, CH2OH, halogen, aryl, heteroaryl, acyl, acyloxy, amino, etc.; Q = O, S, NR7; W = CR8R9; X, Y = H2, O; R7 = H, alkyl, heterocyclylalkyl, etc.; R8, R9 = H, OH, cycloalkyl, cycloalkylmethyl, heterocyclyl, heterocyclylalkyl, etc.], were prepd. for use as agents for the regulation of protein kinase and for the treatment of prostate disorders, neoplasia, rheumatoid arthritis, pulmonary fibrosis, etc. Thus, II (R = oxiranylmethyl) was prepd. in 71% yield by via reaction of (.+-.)-glycidyl mesylate and Rink's acid resin bound 6,7,12,13-tetrahydro-5H-indeno[2,1-a]pyrrolo[3,4-c]carbazol-5-one. The prepd. compds. were tested for inhibitory activity against a variety of protein kinases, such as trkA tyrosine kinase, vascular endothelial growth factor receptor kinase, protein kinase C, etc.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2000:227509 CAPLUS

DN 132:260705

TI Methods using fused pyrrolocarbazole compounds for preventing/treating damage to sensory hair cells and cochlear neurons

IN Ylikoski, Jukka; Pirvola, Ulla; Saarma, Mart; Walton, Kevin; Hudkins, Robert L.

PA Cephalon, Inc., USA

SO PCT Int. Appl., 232 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

ΡI

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2000018407 A1 20000406 WO 1999-US21780 19990924

```
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9960532
                            20000417
                                          AU 1999-60532
                                                            19990924
                       A1
     EP 1126855
                       A1
                            20010829
                                           EP 1999-969678
                                                            19990924
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
PRAI US 1998-101763P
                     P
                            19980925
     WO 1999-US21780
                      W
                            19990924
os
     MARPAT 132:260705
AΒ
     Methods for preventing or treating damage to sensory hair cells and
     cochlear neurons are disclosed. The methods comprise the administration
     of an effective amt. of a fused pyrrolocarbazole compd. (Markush
     included). The method provides for the prevention/treatment of both
     hearing loss and loss of the sense of balance. Prepn. of compds. of the
     invention is described.
RE.CNT 3
              THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L10
    ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN
     2000:161543 CAPLUS
DN
     132:217150
ΤI
     Methods for identification of compounds modulating multiple lineage kinase
     proteins, compound preparation, and therapeutic use
IN
     Maroney, Anna; Walton, Kevin M.; Dionne, Craig A.; Neff, Nicola; Knight,
     Ernest, Jr.; Glicksman, Marcie A.
     Cephalon, Inc., USA
PA
     PCT Int. Appl., 158 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
    English
FAN.CNT 1
     PATENT NO.
                      KIND DATE
                                           APPLICATION NO.
                           -----
                                           -----
PΙ
     WO 2000013015
                            20000309
                                           WO 1999-US18864 19990818
                     A1
            AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
            CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
            IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
            MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
            SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
            KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
            ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
            CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    AU 9956793
                      Α1
                            20000321
                                          AU 1999-56793
                                                            19990818
    EP 1105728
                                           EP 1999-943759
                      A1
                            20010613
                                                            19990818
           AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    BR 9913190
                      Α
                            20011211
                                           BR 1999-13190
                                                            19990818
    NO 2001000389
                            20010402
                                           NO 2001-389
                                                            20010123
PRAI US 1998-97980P
                       Р
                            19980826
    WO 1999-US18864
                      W
                            19990818
os
    MARPAT 132:217150
AB
    Methods for identifying compds. which modulate activity of a multiple
    lineage kinase protein and promotes cell survival or cell death comprise
    contacting the cell contg. the multiple lineage kinase protein with the
    compd., detg. whether the compd. decreases activity of the multiple
    lineage kinase protein, and detg. whether the compd. promotes cell
```

survival are provided. Methods for identifying compds. which may be useful in the treatment of neurodegenerative disorders and/or inflammation are also provided. Methods for modulating the activity of a multiple lineage kinase protein comprising contacting the protein or a cell contg. the protein with an indeno- or indolo- compd. of the invention are also provided. Methods of treating neurodegenerative disorders and/or inflammation are also provided.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
T-10
      ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS
ΑN
      1999:783942 CAPLUS
DN
      132:23129
TI
      Bridged indenopyrrolocarbazoles
IN
      Singh, Jasbir; Hudkins, Robert L.; Mallamo, John P.; Underiner, Theodore
      L.; Tripathy, Rabindranath
PA
      Cephalon, Inc., USA
SO
      PCT Int. Appl., 90 pp.
      CODEN: PIXXD2
DT
      Patent
LΑ
      English
FAN.CNT 1
      PATENT NO.
                          KIND DATE
                                                    APPLICATION NO.
                                                                         DATE
      ---
                           ----
                                  -----
                                                     -----
                                                    WO 1999-US12531 19990604
PΙ
      WO 9962523
                           A1
                                  19991209
          W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
               RU, TJ, TM
           RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
                ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
                CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      US 6127401
                           Α
                                  20001003
                                                    US 1999-325140
                                                                         19990603
      AU 9944188
                            A1
                                  19991220
                                                    AU 1999-44188
                                                                         19990604
      AU 744900
                           B2
                                  20020307
      EP 1083903
                                                    EP 1999-927234
                           A1
                                  20010321
                                                                         19990604
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, SI, LT, LV, FI, RO
      BR 9910908
                           Α
                                  20011002
                                                    BR 1999-10908
                                                                         19990604
      US 6359130
                            B1
                                  20020319
                                                    US 2000-572160
                                                                         20000517
      NO 2000006166
                                                    NO 2000-6166
                            Α
                                  20010207
                                                                         20001204
PRAI US 1998-88114P
                           Ρ
                                  19980605
      US 1999-325140
                           Α
                                  19990603
      WO 1999-US12531
                            W
                                  19990604
os
      MARPAT 132:23129
GI
```

$$R^{1}$$
 R^{1}
 R^{1}
 R^{1}
 R^{2}
 R^{2}
 R^{5}
 R^{6}

Ι

$$R^1$$
 R^1
 R^3
 R^3
 R^4
 R^2
 R^5
 R^6

AB Synthesis and activity of bridged indenopyrrolocarbazoles (I) [R1 = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heteroaryl, (un)substituted heteroarylalkyl, acyl, (un)substituted OH, (un)substituted CONH2; R2 = H, (un)substituted alkyl, (un)substituted OH, (un)substituted arylalkyl, (un)substituted heteroarylalkyl; R3 and R4 independently = H, aryl, heteroaryl, F, Cl, Br, I, CN, CF3, NO2, (un)substituted OH, (un)substituted O acyl, (un)substituted NH2, (un)substituted NHSO3H, (un)substituted NH acyl, (un)substituted alkyl; R5 and R6 independently = H, (un)substituted alkyl, (un)substituted arylalkyl, (un)substituted heteroarylalkyl; Y = O, S, (un)substituted NH, CH2; Z = bond, O, CH=CH, S, CO, (un)substituted CH(OH); A and B = 2H, O, S, (un)substituted N with the proviso that one of them is O] is disclosed. I are useful in the treatment of numerous diseases.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ι

L10 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1998:31143 CAPLUS

DN 128:114942

TI Preparation of fused pyrrolocarbazoles as drugs.

IN Hudkins, Robert L.; Knight, Ernest, Jr.

PA Cephalon, Inc., USA

SO U.S., 51 pp. Cont.-in-part of U.S. 5,594,009. CODEN: USXXAM

DT Patent

LA English

FAN. CNT 5

FAM.CM	. э					
			DATE	APPLICATION NO.	DATE	
					19950911	
US	5475110	Α	19951212	US 1994-323755	19941014	
US	5591855	Α	19970107	US 1995-427160	19950424	
US	5594009	Α	19970114	US 1995-452335	19950526	
WC	9611933	A1	19960425	WO 1995-US12761	19951003	
	W: AM,	AU, BB, BC	B, BR, BY, CA,	CN, CZ, EE, FI, GE	, HU, JP, KG, KP,	
				NO, NZ, PL, RO, RU		
		UZ, VN				
	RW: AT,	BE, CH, DE	E, DK, ES, FR,	GB, GR, IE, IT, LU	, MC, NL, PT, SE	
Αl	9539986	A1	19960506	AU 1995-39986	19951003	
JA	705306	B2	19990520			
E	785938	A1	19970730	EP 1995-938713	19951003	
E	785938	B1	20020102			
	R: AT,	BE, CH, DE	, DK, ES, FR,	GB, GR, IE, IT, LI	, LU, MC, NL, PT, SE	
BF				BR 1995-9348		
				EP 2000-204170		
				GB, GR, IT, LI, LU		
	•			, , ,	,,,	

		IE, LT, L	v				
	JР	2001509775	T2	20010724	JΡ	1996-513289	19951003
	AT	211472	E	20020115	AΤ	1995-938713	19951003
	FΙ	9701479	Α	19970611	FI	1997-1479	19970409
	NO	9701677	Α	19970611	NO	1997-1677	19970411
PRAI	US	1994-323755	A2	19941014			
	US	1995-427160	A2	19950424			
	US	1995-452335	A2	19950526			
	US	1995-526798	A	19950911			
	\mathbf{EP}	1995-938713	A 3	19951003			
	WO	1995-US12761	W	19951003			
os	MAI	RPAT 128:114942					
GI							

I

Title compds. [I; B, F = atoms to form unsatd. 5-6 membered (hetero)cycles; R1 = H, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, acyl; R2 = H, acyl, alkyl, alkenyl, alkynyl, (substituted) monosaccharide residue; R3-R6 = H, aryl, heteroaryl, halo, cyano, CF3, NO2, (substituted) OH, amino, etc.; A1, A2, B1, B2 = (H, H), (H, OR11), (H, SR11), [H, N(R11)2]; A1A2, B1B2 = O, S, NR11; R11 = H, alkyl, aryl, heteroaryl; X = (substituted) alkylene, CH:CH, O, S, SO, SO2, CO, etc.; with provisos], were prepd. for effecting the function and/or survival of trophic factor responsive cells; inhibition of enzymic activity; inhibition of inflammation-assocd. responses; inhibition of cell growth assocd. with hyperproliferative states; and inhibition of developmentally programmed motoneuron death. Thus, 3-fluoro-5H,6H,12H,13H-indeno[2,3-a]pyrrolo[3,4-c]carbazole-7-one (prepn. given) at 250 nM increased choline acetyltransferase activity in rat fetal basal forebrain prepns. by 389%.

L10 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1997:70359 CAPLUS

DN 126:171583

TI Preparation of indeno[2,3-a]pyrrolo[3,4-c]carbazolediones and analogs as drugs

IN Hudkins, Robert L.; Knight, Ernest, Jr.

PA Cephalon, Inc., USA

SO U.S., 46 pp. Cont.-in-part of U.S. Ser. No. 427, 160. CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5

	ימס	FENT	NΩ		KI	MTD.	DATE			70.1	ד זממ	CAMT.	ONT NT	^				
	I.A.	LINI	110.		KI	עט	DAIE			A.	PPT	CATI	ON NO	Ο.	DATE			
												-			- -	- -		
ΡI	US	5594	009		Α		1997	0114		U	5 19	95-4	5233	5	1995	0526		
	US	5475	110		Α		1995	1212		US	3 19	94-3	2375	5	1994	1014		
	US	5591	855		Α		1997	0107		US	3 19	95-4	2716	0	1995	0424		
	US	5705	511		Α		1998	0106		US	5 19	95-5	2679	8	1995	0911		
	WO	9611	933		A:	1	1996	0425		W	19	95-U	S127	61	1995	1003		
		W:	AM,	AU,	BB,	BG,	BR,	BY,	CA,	CN,	CZ,	EE,	FI,	GE,	HU,	JP,	KG,	KP,
			KR,	ΚZ,	LK,	LT,	LV,	MG,	MX,	NO,	NZ,	PL,	RO,	RU,	SG,	sĸ,	TJ,	TT,
			UA,	UΖ,	VN								•	•	•	,	- /	•

```
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9539986
                             19960506
                        A1
                                            AU 1995-39986
                                                              19951003
     AU 705306
                        B2
                             19990520
     EP 785938
                        A1
                             19970730
                                             EP 1995-938713
                                                              19951003
     EP 785938
                        В1
                             20020102
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     BR 9509348
                                            BR 1995-9348
                        Α
                             19971104
                                                              19951003
     EP 1088823
                        A1
                             20010404
                                            EP 2000-204170
                                                              19951003
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
         R:
              IE, LT, LV
     JP 2001509775
                        T2
                             20010724
                                            JP 1996-513289
                                                              19951003
     AT 211472
                        Е
                             20020115
                                            AT 1995-938713
                                                              19951003
     FI 9701479
                        Α
                             19970611
                                            FI 1997-1479
                                                              19970409
     NO 9701677
                        Α
                             19970611
                                            NO 1997-1677
                                                              19970411
PRAI US 1994-323755
                             19941014
                       A2
     US 1995-427160
                       A2
                             19950424
     US 1995-452335
                       A2
                             19950526
     US 1995-526798
                       Α
                             19950911
     EP 1995-938713
                       Α3
                             19951003
     WO 1995-US12761
                       W
                             19951003
     MARPAT 126:171583
os
GI
```

AB Title compds. [I; A1,A2,B1,B2 = H, OH, alkoxy, etc.; A1A2, B1B2 = O; R1 = H, alkyl, (hetero)aryl(alkyl), alkanoyl, etc.; R2 = H, alkyl(sulfonyl), alkoxycarbonyl, etc.; R3-R6 = H, halo, alkyl, alkoxy, etc.; X = alkylene, O, S, CH:CH, etc.] were prepd. as neuronal cell protectants, trophic factor enhancers, protein kinase C and tyrosine kinase inhibitors, etc. Thus, 2-indanone was alkylated with indole and the dehydrated product cyclocondensed with maleimide to give, after dehydrogenation, title compd. II. Data for biol. activity of I were given.

L10 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1997:49296 CAPLUS

DN 126:157494

TI Preparation of indeno[2,1-a]pyrrolo[3,4-c]carbazoles and analogs as drugs

```
PA
     Cephalon, Inc., USA
     U.S., 40 pp. Cont.-in-part of U.S. 5,475,110.
 SO
     CODEN: USXXAM
DT
     Patent
     English
LA
FAN.CNT 5
     PATENT NO.
                      KIND DATE
                                           APPLICATION NO. DATE
     -----
                      ----
                                           -----
PΙ
     US 5591855
                       Α
                            19970107
                                           US 1995-427160
                                                            19950424
     US 5475110
                       Α
                            19951212
                                           US 1994-323755
                                                            19941014
     US 5594009
                       Α
                            19970114
                                           US 1995-452335
                                                            19950526
     US 5705511
                       Α
                            19980106
                                           US 1995-526798
                                                            19950911
     WO 9611933
                       A1
                            19960425
                                           WO 1995-US12761 19951003
         W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP,
             KR, KZ, LK, LT, LV, MG, MX, NO, NZ, PL, RO, RU, SG, SK, TJ, TT,
             UA, UZ, VN
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9539986
                       A1 19960506
                                          AU 1995-39986
                                                           19951003
     AU 705306
                       B2
                            19990520
     EP 785938
                       A1
                            19970730
                                          EP 1995-938713
                                                           19951003
     EP 785938
                           20020102
                       B1
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     BR 9509348
                       Α
                            19971104
                                          BR 1995-9348
                                                           19951003
     EP 1088823
                       A1
                            20010404
                                          EP 2000-204170
                                                           19951003
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, LT, LV
     JP 2001509775
                      T2
                            20010724
                                          JP 1996-513289
                                                           19951003
     AT 211472
                      \mathbf{E}
                            20020115
                                          AT 1995-938713
                                                           19951003
     FI 9701479
                      Α
                            19970611
                                          FI 1997-1479
                                                           19970409
    NO 9701677
                      Α
                           19970611
                                          NO 1997-1677
                                                           19970411
PRAI US 1994-323755
                      A2
                           19941014
    US 1995-427160
                      A2
                           19950424
    US 1995-452335
                      A2
                           19950526
    US 1995-526798
                      Α
                           19950911
    EP 1995-938713
                      A3
                           19951003
    WO 1995-US12761
                      W
                           19951003
OS
    MARPAT 126:157494
GΙ
```

Hudkins, Robert L.; Knight, Ernest, Jr.

IN

Title compds. [I; A1,A2,B1,B2 = H and OR11, H and N(R11)2, etc.; A1A2,B1B2 = H2, O, S, NR11; R1 = H, alkyl, (hetero)aryl(alkyl), etc.; R2 = H, alkyl, alkoxycarbonyl, etc.; R3-R6 = H, halo, alkyl, alkoxy, etc.; R11 = H, alkyl, aryl, etc.; Z = O, S, CH2, CH:CH, CO, etc.] were prepd. as neuronal cell survival promoters, protein kinase inhibitors, antiproliferatives, antiinflammatories, etc. Thus, indole was condensed with 2-indanone and the dehydrated product cyclocondensed with maleimide to give, after DDQ dehydrogenation, title compd. II. Data for biol. activity of I were given.

```
L10 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS
```

AN 1996:457759 CAPLUS

DN 125:114935

TI Preparation of fused pyrrolocarbazoles as inhibitors of protein kinase C and protein tyrosine kinase

IN Hudkins, Robert L.; Knight, Ernes, Jr.

PA Cephalon, Inc., USA

SO PCT Int. Appl., 160 pp. CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND DATE	APPLICATION NO. DATE
PI	W: AM, AU,	BB, BG, BR, BY, CA, LK, LT, LV, MG, MX,	WO 1995-US12761 19951003 CN, CZ, EE, FI, GE, HU, JP, KG, KP, NO, NZ, PL, RO, RU, SG, SK, TJ, TT,
	US 5591855 US 5594009 US 5705511 AU 9539986 AU 705306 EP 785938	A 19951212 A 19970107 A 19970114 A 19980106 A1 19960506 B2 19990520 A1 19970730	GB, GR, IE, IT, LU, MC, NL, PT, SE US 1994-323755 19941014 US 1995-427160 19950424 US 1995-452335 19950526 US 1995-526798 19950911 AU 1995-39986 19951003 EP 1995-938713 19951003
]	DK 3303348	B1 20020102 CH, DE, DK, ES, FR, A 19971104	GB, GR, IE, IT, LI, LU, MC, NL, PT, SE BR 1995-9348 19951003 JP 1996-513289 19951003

	AT 211472 FI 9701479	E A	20020115	AT 1995-938713	19951003
		A	19970611	FI 1997-1479	19970409
	NO 9701677	A	19970611	NO 1997-1677	19970411
PRAI	US 1994-323755	Α	19941014		
	US 1995-427160	Α	19950424		
	US 1995-452335	A	19950526		
	US 1995-526798	A	19950911		
	WO 1995-US12761	W	19951003		
OS GI	MARPAT 125:114935				

The title compds. [I; E1 and E2 are 6-membered carbocyclic arom. rings in AB which 1-3 carbon atoms may be replaced by N, or 5-membered carbocyclic arom. rings in which one carbon atom is replaced with O, N, or S, or 2 carbon atoms are replaced with S and N or O and N; A1 = A2 = H, A1A2 = O, etc.; B1 = B2 = H, B1B2 = O, etc.; R1 = H, alkyl, heteroaryl, aralkyl, aryl, etc.; R2 = H, alkyl, alkenyl, alkynyl, S02-R9, C02-R9, CO-R9 where R9 = alkyl, aryl; R3-R6 = H, aryl, F, Cl, Br, iodo, cyano, CF3, NO2, OH, etc.; X = (un)substituted alkylene of 1-3 carbon atoms, vinylene, SO2, CO, etc.], inhibitors of protein kinase C and protein tyrosine kinase and therefore useful for cell growth, cell hyperproliferation inhibition, and inflammation inhibition, are prepd. Thus, 4c,7a,7b,12a-tetrahydro-6H, 12H, 13H-indeno[2, 3-a]pyrrolo[3, 4-c]carbazole-5,7(5H,7H)-dione, prepd. from 2-(2-indenyl)indole and maleimide, was treated with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in toluene to give the title compd. 6H,12H,13H-indeno[2,3-a]pyrrolo[3,4-c]carbazole-5,7(5H,7H)-dione. In an assay based on reported by Kikkawa Et al. (1982) this had an IC50 of 0.07 .mu.M against protein kinase C.

L10 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1996:35030 CAPLUS

DN 124:202228

TI Fused pyrrolocarbazoles useful for enhancing the function/survival of neuronal cells and inhibition of protein kinase, inflammation response, and hyperproliferative cell growth

IN Hudkins, Robert L.; Knight, Jr Ernest

PA Cephalon, Inc., USA

SO U.S., 33 pp. CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5475110	 А	19951212	US 1994-323755	19941014
	US 5591855	A	19970107	US 1995-427160	19950424
	US 5594009	A	19970114	US 1995-452335	19950526
	US 5705511 WO 9611933	A A1	19980106	US 1995-526798	19950911
	W: AM, AU,	BB, BG	19960425 , BR, BY, CA,	WO 1995-US12761 CN, CZ, EE, FI, GE	19951003 , HU, JP, KG, KP.

```
KR, KZ, LK, LT, LV, MG, MX, NO, NZ, PL, RO, RU, SG, SK, TJ, TT,
              UA, UZ, VN
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9539986
                        Α1
                             19960506
                                             AU 1995-39986
                                                               19951003
     AU 705306
                        B2
                             19990520
     EP 785938
                        A1
                             19970730
                                             EP 1995-938713
                                                               19951003
     EP 785938
                        B1
                             20020102
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     BR 9509348
                        Α
                             19971104
                                             BR 1995-9348
                                                               19951003
     EP 1088823
                        A1
                             20010404
                                             EP 2000-204170
                                                               19951003
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, LT, LV
     JP 2001509775
                        T2
                             20010724
                                             JP 1996-513289
                                                               19951003
     AT 211472
                        Е
                             20020115
                                             AT 1995-938713
                                                               19951003
     FI 9701479
                        Α
                             19970611
                                             FI 1997-1479
                                                               19970409
     NO 9701677
                        Α
                             19970611
                                             NO 1997-1677
                                                               19970411
PRAI US 1994-323755
                        A2
                             19941014
     US 1995-427160
                        A2
                             19950424
     US 1995-452335
                             19950526
                        A2
     US 1995-526798
                        Α
                             19950911
     EP 1995-938713
                        А3
                             19951003
     WO 1995-US12761
                        W
                             19951003
os
     MARPAT 124:202228
GΙ
```

Disclosed herein are fused pyrrolocarbazoles I wherein: R1 = e.g., H, alkyl of 1-4 carbons, aryl, arylalkyl, heteroaryl, heteroarylalkyl; R2 = H, SO2R9, CO2R9, COR9, alkyl of 1-8 carbons, alkenyl of 1-8 carbons, alkynyl of 1-8 carbons, and a monosaccharide of 5-7 carbons wherein each hydroxyl group of said monosaccharide is independently selected from the group consisting of unsubstituted hydroxyl group and a replacement moiety replacing said hydroxyl group; R9 is selected from the group consisting of alkyl of 1-4 carbons, and aryl; R3, R4, R5, and R6 are each independently

Ι

selected from the group consisting of, e.g., H, aryl, heteroaryl, F, Cl, Br, I, CN, CF3, NO2, OH, OR9; X = e.g., (un) substituted alkylene of 1-3 carbons; (A1,A2) = e.g., (H,H), O, S; (B1,B2) = e.g., (H,H), O, S; with the proviso that at least one of the pairs (A1,A2) or (B1,B2) is O, useful for enhancing the function/survival of neuronal cells and inhibition of protein kinase, inflammation response, and hyperproliferative cell growth. Thus, e.g., 6H,12H,13H-indeno[2,3-a]pyrrolo[3,4-c]carbazole-5,7(5H,7H)-dione II was prepd. via Diels-Alder cycloaddn. of 2-(2-indenyl) indole (prepn. given) with maleimide followed by aromatization of the resultant 4c,7a,7b,12a-tetrahydro-6H,12H,13H-indeno[2,3-a]pyrrolo[3,4-c]carbazole-5,7(5H,7H)-dione. II exhibited a 148% increase (over control) of spinal chord ChaT (choline acetyltransferase) activity in the dissocd. rat embryonic spinal cord culture assay, and an IC50 = 0.07 .mu.M for inhibition of protein kinase C.

=> d hitstr 10

L10 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS

IT 174349-11-2P 174349-21-4P 174349-29-2P 174349-35-0P 174349-53-2P 174349-87-2P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(fused pyrrolocarbazoles useful for enhancing the function/survival of neuronal cells and inhibition of protein kinase, inflammation response, and hyperproliferative cell growth)

RN 174349-11-2 CAPLUS

CN 5H-Indeno[2,1-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 12,13-dihydro-(9CI) (CA INDEX NAME)

RN 174349-21-4 CAPLUS

CN 5H-Indeno[2,1-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 9-fluoro-12,13-dihydro- (9CI) (CA INDEX NAME)

RN 174349-29-2 CAPLUS

CN 5H-Indeno[2,1-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 10-chloro-12,13-dihydro- (9CI) (CA INDEX NAME)

RN 174349-35-0 CAPLUS

CN 5H-Indeno[2,1-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 9-chloro-12,13-dihydro- (9CI) (CA INDEX NAME)

RN 174349-53-2 CAPLUS

CN 5H-Indeno[2,1-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 12,13-dihydro-12-methyl- (9CI) (CA INDEX NAME)

RN 174349-87-2 CAPLUS

CN 5H-Indeno[2,1-a]pyrrolo[3,4-c]carbazole-5,7,13(6H,12H)-trione (9CI) (CA INDEX NAME)

IT 174349-36-1P 174349-44-1P 174349-45-2P 174349-49-6P 174349-88-3P 174349-89-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
 (fused pyrrolocarbazoles useful for enhancing the function/survival of
 neuronal cells and inhibition of protein kinase, inflammation response,
 and hyperproliferative cell growth)

RN 174349-36-1 CAPLUS
CN 5H-Indeno[2,1-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione,
9-bromo-12,13-dihydro- (9CI) (CA INDEX NAME)

RN 174349-44-1 CAPLUS CN 5H-Indeno[2,1-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 3-bromo-12,13-dihydro- (9CI) (CA INDEX NAME)